azilsartan + rosuvastatin + ezetimibe

Treatment C-Celltrion-Hypertension-Hyperlipidemia refers to the combination therapy of CTL0901 and CTL0902, currently being evaluated by Celltrion in Phase 1 clinical trials. CTL0901 is a fixed-dose combination of azilsartan, an angiotensin II receptor blocker (ARB), and rosuvastatin, an HMG-CoA reductase inhibitor (statin). CTL0902 is ezetimibe, a selective cholesterol absorption inhibitor. This triple-combination approach is intended for the management of patients suffering from both hypertension and hyperlipidemia, aiming to reduce cardiovascular risk through multiple synergistic mechanisms: lowering blood pressure by blocking the renin-angiotensin system, and lowering LDL cholesterol by inhibiting both hepatic synthesis and intestinal absorption. The use of such combinations is part of a strategy to improve patient adherence by reducing the daily pill burden.

Other names

Treatment C